Oligovax is an biopharmaceutical company focused on developing innovative therapies. The company's technology approach is based on drug substances consisting of synthetic oligonucleotides (ODNs) containing CpG motifs that have optimized immunostimulating properties. The CpG-ODN "Litenimod" developed by the company is a very powerful Th1 adjuvant when combined with a broad range of antigens, leading to both cytotoxic T lymphocytes (CTL) and antibody immune response.